Oday Hamid

Multicenter Phase II Study of the Oral MEK Inhibitor, CI-1040, in Patients With Advanced Non-Small-Cell Lung, Breast, Colon, and Pancreatic Cancer

John J. Rinehart, Alex A. Adjei, Patricia LoRusso et al. · Journal of Clinical Oncology · 2004 · 639 citations

Medicine, Oncology, Pharmacology +16

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Daniel P. Petrylak, Ronald de Wit, Kim N. et al. · The Lancet · 2017 · 177 citations · Full text

Medicine, Oncology, Pharmacology +15

Phase II Trial of Intravenous CI-1042 in Patients With Metastatic Colorectal Cancer

Oday Hamid, Mary Varterasian, Scott Wadler et al. · Journal of Clinical Oncology · 2003 · 144 citations

Medicine, Oncology, Pharmacotherapy +17

Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial

Tina Cascone, Gozde Kar, Jonathan Spicer et al. · Cancer Discovery · 2023 · 117 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Multicenter, Randomized Phase II Trial of Oral CI-1033 for Previously Treated Advanced Ovarian Cancer

Susana M. Campos, Oday Hamid, Michael V. Seiden et al. · Journal of Clinical Oncology · 2005 · 108 citations · Full text

Medicine, Oncology, Pharmacology +17